2023
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regression
2021
Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries
Cairns M, Ceesay S, Sagara I, Zongo I, Kessely H, Gamougam K, Diallo A, Ogboi J, Moroso D, Van Hulle S, Eloike T, Snell P, Scott S, Merle C, Bojang K, Ouedraogo J, Dicko A, Ndiaye J, Milligan P. Effectiveness of seasonal malaria chemoprevention (SMC) treatments when SMC is implemented at scale: Case–control studies in 5 countries. PLOS Medicine 2021, 18: e1003727. PMID: 34495978, PMCID: PMC8457484, DOI: 10.1371/journal.pmed.1003727.Peer-Reviewed Original ResearchMeSH KeywordsAfrica, WesternAge FactorsAmodiaquineAntimalarialsCase-Control StudiesChild, PreschoolCommunicable Disease ControlDrug CombinationsFemaleHumansIncidenceInfantMalaria, FalciparumMaleParasite LoadPlasmodium falciparumProgram EvaluationPyrimethamineRisk AssessmentRisk FactorsSeasonsSulfadoxineTime FactorsTreatment OutcomeConceptsSeasonal malaria chemopreventionCase-control studyClinical malariaOdds ratioClinical trialsNational Malaria Control ProgrammeClinical malaria incidenceIndividual case-control studiesIncidence rate ratiosHigh protective efficacyConditional logistic regressionMalaria control activitiesMalaria control programmesPersonal protectionCase-control designChemoprevention treatmentMalaria chemopreventionSevere malariaSMC treatmentMean agePrimary exposureProtective efficacyResidual confoundingHealth facilitiesParasite density
2020
Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study
Partnership A, Baba E, Hamade P, Kivumbi H, Marasciulo M, Maxwell K, Moroso D, Roca-Feltrer A, Sanogo A, Johansson J, Tibenderana J, Abdoulaye R, Coulibaly P, Hubbard E, Jah H, Lama E, Razafindralambo L, Van Hulle S, Jagoe G, Tchouatieu A, Collins D, Gilmartin C, Tetteh G, Djibo Y, Ndiaye F, Kalleh M, Kandeh B, Audu B, Ntadom G, Kiba A, Savodogo Y, Boulotigam K, Sougoudi D, Guilavogui T, Keita M, Kone D, Jackou H, Ouba I, Ouedraogo E, Messan H, Jah F, Kaira M, Sano M, Traore M, Ngarnaye N, Elagbaje A, Halleux C, Merle C, Iessa N, Pal S, Sefiani H, Souleymani R, Laminou I, Doumagoum D, Kesseley H, Coldiron M, Grais R, Kana M, Ouedraogo J, Zongo I, Eloike T, Ogboi S, Achan J, Bojang K, Ceesay S, Dicko A, Djimde A, Sagara I, Diallo A, NdDiaye J, Loua K, Beshir K, Cairns M, Fernandez Y, Lal S, Mansukhani R, Muwanguzi J, Scott S, Snell P, Sutherland C, Tuta R, Milligan P. Effectiveness of seasonal malaria chemoprevention at scale in west and central Africa: an observational study. The Lancet 2020, 396: 1829-1840. PMID: 33278936, PMCID: PMC7718580, DOI: 10.1016/s0140-6736(20)32227-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAfrica, CentralAfrica, WesternAmodiaquineAntimalarialsCase-Control StudiesChemopreventionChildCost-Benefit AnalysisDrug CombinationsDrug ResistanceFeasibility StudiesHumansIncidenceMalariaProgram EvaluationPyrimethamineSafetySeasonsSulfadoxineSurveys and QuestionnairesYoung AdultConceptsSeasonal malaria chemopreventionCase-control studyHigh transmission periodMalaria chemopreventionObservational studyHealth-care staff timeHigh malaria transmission seasonDrug resistanceSerious adverse drug reactionsMalaria transmission seasonSerious adverse reactionsSevere skin reactionsCommunity health workersNational health management information systemAdverse drug reactionsCost-effectiveness ratioHealth Management Information SystemIndividual case safetyTarget populationMarker of resistanceSMC treatmentHospital admissionOutpatient clinicDrug reactionsSkin reactions
2015
Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso
Zongo I, Milligan P, Compaore Y, Some A, Greenwood B, Tarning J, Rosenthal P, Sutherland C, Nosten F, Ouedraogo J. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2015, 59: 4387-4396. PMID: 25918149, PMCID: PMC4505196, DOI: 10.1128/aac.04923-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria chemopreventionAlternative drugsControl groupPrimary outcome measureSeasonal malaria transmissionRandomized noninferiority trialPotential alternative drugDihydroartemisinin-PiperaquinePfdhps mutationsClinical malariaMalaria attacksSulfadoxine-pyrimethamineOdds ratioNoninferiority trialOutcome measuresDHAPQChildren 3Malaria transmissionDrug resistanceAntifolate resistanceChemopreventionChildrenAmodiaquineTrials
2013
Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission
Tahita M, Tinto H, Menten J, Ouedraogo J, Guiguemde R, van Geertruyden J, Erhart A, D’Alessandro U. Clinical signs and symptoms cannot reliably predict Plasmodium falciparum malaria infection in pregnant women living in an area of high seasonal transmission. Malaria Journal 2013, 12: 464. PMID: 24373481, PMCID: PMC3877878, DOI: 10.1186/1475-2875-12-464.Peer-Reviewed Original ResearchConceptsPregnant womenMalaria infectionRapid diagnostic testsCommon signsPredictive valuePlasmodium falciparum malaria infectionMajor public health problemDiagnostic testsCommon malaria symptomsHigh seasonal transmissionFalciparum malaria infectionHistory of feverSymptoms of malariaPublic health problemPositive predictive valueIntensity of transmissionClinical malariaClinical presentationGestational ageMalaria symptomsDistrict hospitalOverall prevalenceMaternity clinicsClinical signsEndemic countries
1996
Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso
MIGOT F, OUEDRAOGO J, DIALLO J, ZAMPAN H, DUBOIS B, SCOTT‐FINNIGAN T, .SANOU P, DELORON P. Selected P. falciparum specific immune responses are maintained in AIDS adults in Burkina Faso. Parasite Immunology 1996, 18: 333-339. PMID: 9229386, DOI: 10.1046/j.1365-3024.1996.d01-116.x.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAnimalsAntigens, ProtozoanBurkina FasoCase-Control StudiesCD4 Lymphocyte CountCD4-Positive T-LymphocytesCytokinesHIV-1HumansIn Vitro TechniquesInterferon-gammaInterleukin-2Interleukin-4Lymphocyte ActivationMalaria, FalciparumMiddle AgedPlasmodium falciparumConceptsImmune responseSchizont extractCytokine productionHIV-1Healthy subjectsHIV-1-positive subjectsSpecific human immune responsesCrude schizont extractNegative healthy subjectsPlasmodium falciparum malariaHIV-1 infectionIL-4 productionSpecific immune responseHuman immune responseWhole blood culturesIL-2 productionPresence of PHAMerozoite surface proteinAIDS adultsLymphocyte subsetsFalciparum malariaClinical AIDSAIDS patientsPositive subjectsMalarial antigens